News & Media

Norbrook launches Carprieve® Chewable Tablets for Dogs

Friday 12 May 2017   
Norbrook launches Carprieve® Chewable Tablets for Dogs

Norbrook Laboratories has today announced the launch of Carprieve® Chewable Tablets for Dogs in the United States. This new product completes the US Carprieve® (carprofen) portfolio from Norbrook which includes Carprieve® Injection and Carprieve® Caplets. The flavoured chewable tablet offers the veterinarian an easy to administer option designed for the relief of pain and inflammation associated with osteoarthritis. This non-steroidal anti-inflammatory drug (NSAID) is also indicated for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

Richard Palmer, Global Head of Sales and Marketing, Norbrook said, “We are delighted to extend our companion animal portfolio in the US with the launch of Carprieve Chewable Tablets. We are committed to growing our North America business and continuing to develop companion animal products in line with the needs of our Customers.

 “We have embarked on a significant multi-year capital investment programme, which includes the upgrading and expansion of our manufacturing capability, new laboratory facilities, and new product development. We have made a significant investment in the manufacturing and packaging process for this new tablet to enable us to bring a high quality, cost effective product to market.”

 Jonathan Whitt, Marketing Manager – Companion Animals US, Norbrook added, “Carprofen is one of the most widely prescribed non-steroidal anti-inflammatory drugs (NSAID) used in the management of joint pain associated with osteoarthritis as well as post-operative pain associated with soft tissue surgeries like spaying, neutering and dental procedures. Carprieve Chewable Tablets offer the veterinarian more choice when selecting the correct pain management product and a cost effective equivalent to the pioneer. This new addition further supports the expansion of Norbrook’s companion animal portfolio in the US.”

 Carprieve Chewable Tablets have the same active ingredient (carprofen) and dosing regimen and have demonstrated bioequivalence in the target species to the pioneer. Carprieve Chewable Tablets are available in 25 mg, 75 mg, and 100 mg strengths and in 30, 60 or 180 count bottles. For more information about Carprieve® Chewable Tablets (carprofen)for dogs, please contact your veterinarian products distributoror visit www.norbrook.com .

Notes:

Carprieve Chewable Tablets (carprofen) for Dogs

Observe label directions. Do not use in cats. As with other NSAIDs, rare but serious side effects involving the digestive system, kidneys or liver may occur.  Such signs may be serious, resulting in hospitalization or even death.  Regular monitoring is required for pets on medication.  Pet owners should be advised to discontinue if side effects occur and contact their veterinarian.  See product labeling for full product information.